Suven Life Sciences Limited (SUVEN)
₹303.55 +1.10% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Suven Life's revenue was ₹4.0 Cr (+114.3% year on year, +163.1% on the previous quarter), and net profit ₹-128 Cr (a bigger loss than a year earlier); the operating margin was -3300.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹4.0 | +114.3% | +163.1% |
| Operating profit | ₹-132 | loss widened | loss widened |
| Net profit | ₹-128 | loss widened | loss widened |
| EPS (₹) | -4.83 | loss widened | loss widened |
| Operating margin | -3300.0% | — | — |
SUVEN delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 36.27% of the SUVEN shares traded on NSE were taken to delivery, against the stock's own 20-session average of 46.05%. That is lower than usual for this stock.
Delivery in the last 5 sessions: 29.9% · 39.1% · 44.8% · 17.4% · 36.3%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Suven Life Sciences has completed patient enrollment in its global Phase-3 clinical study of lead asset Masupirdine (SUVN-502) for Agitation associated with Alzheimer's Dementia (AAD). A total of 424 patients were randomized across sites in the USA and Europe, exceeding the original target of 375 patients. The last patient last visit is projected by end of December 2026, with database lock by March 2027 and topline clinical results expected by May 2027. As a pure-play clinical biopharma firm with TTM revenues of Rs 9 Cr and net losses of Rs 241 Cr, SUVN-502 is the company's primary value driver.
- Randomized 424 patients across USA and Europe, surpassing the planned target of 375 patients
- Trial tests Masupirdine (50 mg, 100 mg, vs placebo) once daily over 12 weeks for Alzheimer's agitation
- Last patient last visit (LPLV) anticipated by end of December 2026
- Database lock targeted for end of March 2027, with topline trial results expected by May 2027
Suven Life Sciences concluded its 37th Annual General Meeting on August 25, 2026, with shareholders approving all five resolutions by substantial majorities. Notable approvals included the adoption of FY26 audited financial statements (99.9984% in favor) and a special resolution approving a variation in the utilization of funds raised through a preferential issue (99.9811% in favor). Shareholders also approved a related-party transaction concerning the appointment of Dr. Madhavi Jasti to an office of profit in overseas wholly-owned subsidiaries (99.8262% in favor, with promoter shares abstaining). A total of 152 members attended the meeting via video conference.
- All 5 resolutions passed with over 99.8% voting support.
- Variation in the utilization of funds raised via preferential issue approved with 99.9811% votes in favor.
- Related-party appointment of Dr. Madhavi Jasti approved with 3,15,46,934 votes in favor and 18,50,01,155 votes abstaining.
- A total of 152 shareholders attended the 37th AGM held virtually on August 25, 2026.
Suven Life Sciences reported a consolidated net loss of ₹127.61 Cr for Q1 FY27, a sharp increase from the ₹45.60 Cr loss in the previous quarter. This widening loss is primarily driven by a nearly 3x surge in R&D expenses, which reached ₹123.83 Cr as clinical trial activities likely intensified. While revenue from operations grew to ₹3.57 Cr from ₹1.52 Cr sequentially, the company remains in a high-burn phase typical of NCE-focused biotechs. The company is currently utilizing proceeds from a ₹857.64 Cr warrant issue to fund operations, with ₹448.14 Cr remaining as of June 30, 2026.
- Consolidated net loss widened to ₹127.61 Cr in Q1 FY27 compared to ₹45.60 Cr in Q4 FY26
- R&D expenses surged to ₹123.83 Cr, representing 89.3% of total consolidated expenses
- Revenue from operations stood at ₹3.57 Cr, a 135% increase from the previous quarter's ₹1.52 Cr
- The company has a remaining balance of ₹448.14 Cr from preferential issue proceeds of ₹857.64 Cr
- Employee benefit expenses included ₹1.46 Cr related to ESOPs granted during the quarter
Suven Life Sciences has notified shareholders regarding the availability of its Annual Report for the financial year ended March 31, 2026. The document is accessible via the company's website for those whose email addresses are not registered with the RTA. The company also emphasized the mandatory requirement for updating PAN and KYC details to receive future payments, including dividends. Additionally, a dedicated Senior Citizens Investor Cell has been highlighted to assist shareholders over 60 years of age.
- Annual Report for the Financial Year ended March 31, 2026, is now available on the company website.
- Shareholders must update KYC/PAN details to ensure eligibility for future electronic payments.
- A dedicated toll-free number 1800 3094 006 has been established for senior citizen assistance.
- The company reported a significant net loss of ₹276.34 Cr for FY26 against a revenue of only ₹7.11 Cr.
Suven Life Sciences has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, highlighting its focus as a pure-play R&D entity. The company reported a total turnover of ₹7.11 crore for the fiscal year, with 100% of revenue derived from scientific research and technical services. Exports remain a critical component, accounting for 70% of the total turnover. The company maintains a specialized workforce of 142 permanent employees and identifies clinical trial success as its primary material risk and opportunity.
- Total turnover for FY 2025-26 was ₹7.11 crore, generated entirely from R&D services.
- Exports contributed 70% of the total turnover, serving 4 international countries.
- The company employs 142 permanent staff with a turnover rate of 9.28% in FY26.
- Women represent 33.33% of the Board of Directors and 50% of Key Management Personnel.
- 21% of input materials were sourced directly from MSMEs or small producers.
Suven Life Sciences has scheduled its 37th AGM for August 25, 2026, to seek approval for several key resolutions. Most notably, the company proposes a Related Party Transaction (RPT) to appoint Dr. Madhavi Jasti (daughter of the CMD) to its US and Singapore subsidiaries with a remuneration package starting at USD 400,000 and capped at USD 1,000,000 per annum. Additionally, the company is seeking to reallocate unutilized funds from its June 2025 preferential issue. These proposals are significant given the company's current financial state, reporting a TTM net loss of ₹276 Cr on a revenue of only ₹7 Cr.
- Proposed initial remuneration of USD 400,000 per annum for Dr. Madhavi Jasti in overseas subsidiaries.
- Maximum remuneration cap for the related party transaction set at USD 1,000,000 per annum.
- Proposal to vary the utilization of proceeds from the preferential issue approved on June 5, 2025.
- AGM scheduled for August 25, 2026, with a remote e-voting cut-off date of August 18, 2026.
- Company reported a TTM operating profit margin of -3998.8% and a net loss of ₹276 Cr.
Suven Life Sciences has scheduled an in-person interaction with analysts and institutional investors in Mumbai on July 17, 2026. The company is currently in a pre-revenue R&D phase with a TTM revenue of only Rs 7 Cr and a significant TTM loss of Rs 276 Cr. Investors will likely be looking for updates on the lead NCE candidate SUVN-502, especially following the recent fundraise of Rs 299.54 Cr intended to fund clinical trials. No unpublished price-sensitive information is expected to be disclosed during this routine interaction.
- Investor and analyst meeting scheduled for July 17, 2026, in Mumbai.
- Interaction will be conducted in-person through both group and one-on-one sessions.
- Company recently raised Rs 299.54 Cr in H1 FY26 to support ongoing clinical trial obligations.
- TTM revenue remains minimal at Rs 7 Cr against a market capitalization of Rs 7,747 Cr.
- Lead candidate SUVN-502 for Alzheimer's remains the primary focus for future commercialization.
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15. The presentations will feature updates on the Global Phase-3 study of Masupirdine for Alzheimer's-related agitation and the Phase-2 program for Usmarapride. As a pre-revenue R&D firm with a TTM loss of Rs 276 Cr and revenue of only Rs 7 Cr, these clinical updates are the primary drivers of its Rs 8,127 Cr market valuation. The company is also actively seeking strategic partnering and out-licensing opportunities for its CNS portfolio during the event.
- Presenting 5 scientific posters covering Phase-1 to Phase-3 clinical assets at AAIC-2026
- Providing updates on the Global Phase-3 Masupirdine study targeting agitation in Alzheimer's Dementia
- Showcasing the Usmarapride Phase-2 clinical development program for cognitive disorders
- Company maintains 5 clinical-stage assets and 7 research pipeline projects in the CNS space
- Utilizing Rs 299.54 Cr raised in H1 FY26 to fund ongoing clinical trial obligations
Suven Life Sciences has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended June 30, 2026. The document, issued by Kfin Technologies Limited (the RTA), confirms that securities dematerialized or rematerialized during the quarter have been reported to the stock exchanges. This is a standard administrative filing required for all listed entities and does not impact the company's financial position or its ongoing clinical trials for NCEs like SUVN-502.
- Compliance certificate issued for the quarter ended June 30, 2026
- Registrar and Share Transfer Agent (RTA) Kfin Technologies Limited provided the certification
- Confirmation that dematerialization details were furnished to both BSE and NSE
- Filing dated July 08, 2026, following the RTA certificate dated July 01, 2026
Suven Life Sciences has successfully raised ₹248.84 Cr through the conversion of 1.85 Cr warrants by 17 non-promoter entities at ₹134 per share. This capital infusion is massive for a company with a TTM revenue of only ₹7 Cr and significant R&D losses. Additionally, the board approved incorporating a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a substantial investment commitment of up to USD 100 million. These funds are likely earmarked for advancing clinical trials of their neurodegenerative disorder pipeline, including SUVN-502.
- Allotment of 1,85,70,133 equity shares at ₹134 each upon warrant conversion
- Total consideration of ₹248.84 Cr received from 17 non-promoter investors
- Approved investment of up to USD 100 million in a new Singapore subsidiary
- Paid-up equity capital increased from 26.39 Cr shares to 28.25 Cr shares
- Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term
Suven Life Sciences has successfully raised Rs 248.84 crore by allotting 1.86 crore equity shares to 17 non-promoter entities following warrant conversions at Rs 134 per share. This capital infusion is massive compared to the company's TTM revenue of just Rs 7 crore, providing a significant R&D runway. Simultaneously, the board approved the incorporation of a wholly-owned subsidiary in Singapore, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million (approx. Rs 835 crore). This new entity will focus on the clinical development and commercialization of therapeutics for neurological disorders.
- Allotted 1,85,70,133 equity shares at Rs 134 per share upon conversion of warrants
- Total consideration received from 17 non-promoter allottees amounts to Rs 248.84 crore
- Planned investment of USD 100 million in a new Singapore-based clinical development subsidiary
- Paid-up equity share capital increased to 28,25,62,686 shares from 26,39,92,553 shares
- Re-appointed Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term starting January 2027
Suven Life Sciences has approved the incorporation of a wholly-owned subsidiary in Singapore with a planned investment of USD 100 million (approx. ₹835 Cr) to focus on clinical development of therapeutics. Simultaneously, the company raised ₹248.84 Cr through the allotment of 1.85 crore equity shares following the conversion of warrants at ₹134 per share. The board also confirmed the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second five-year term starting January 2027. These moves provide significant liquidity for a company currently reporting a TTM loss of ₹276 Cr while pursuing high-stakes Alzheimer's drug trials.
- Allotment of 1,85,70,133 equity shares at ₹134 each, raising a total of ₹248.84 Cr
- Planned investment of USD 100 million in a new Singapore-based subsidiary, Suven Neurosciences Pte. Ltd.
- Paid-up equity share capital increased to 28,25,62,686 shares from 26,39,92,553 shares
- Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term effective Jan 21, 2027
- Investment in Singapore subsidiary represents approximately 55% of the company's current net worth of ₹1503 Cr
Suven Life Sciences has allotted 1.85 crore equity shares to 17 non-promoter entities following the conversion of warrants at ₹134 per share, raising ₹248.84 crore. This capital injection is highly material, representing approximately 16.5% of the company's net worth and over 35x its TTM revenue of ₹7 crore. Additionally, the board approved the incorporation of a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million. These funds are critical for a pre-revenue biopharma firm to sustain clinical trials for its neurodegenerative disorder treatments.
- Allotment of 1,85,70,133 equity shares to 17 non-promoter investors upon warrant conversion
- Total cash consideration received from allottees amounts to ₹248,83,97,822
- Planned investment of USD 100 million in a new Singapore-based wholly owned subsidiary
- Conversion price of ₹134 per share is at a significant discount to the current market price of ₹320.8
- Paid-up equity share capital increased from 26.40 crore shares to 28.26 crore shares
Suven Life Sciences has allotted 1.85 crore equity shares to 17 non-promoter entities following the conversion of warrants at ₹134 per share, raising ₹248.84 crore. This capital injection is massive for a company with only ₹7 crore in TTM revenue, providing critical liquidity for its R&D-heavy operations. Additionally, the board approved the incorporation of a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million. These funds are likely earmarked for advancing clinical trials of their lead NCE candidates like SUVN-502.
- Allotment of 1,85,70,133 equity shares at an issue price of ₹134 per share
- Total consideration of ₹248.84 Cr received from 17 non-promoter investors
- Planned investment of USD 100 million in a new Singapore-based wholly-owned subsidiary
- Paid-up equity capital increased from 26.40 crore shares to 28.26 crore shares
- Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term starting Jan 2027
Suven Life Sciences has announced the closure of its trading window for all designated persons starting July 1, 2026. This action is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the release of quarterly financial results. The window will remain closed until 48 hours after the un-audited financial results for the quarter ended June 30, 2026, are declared. The company will communicate the specific date for the Board Meeting to consider these results in due course.
- Trading window closure effective from July 1, 2026, for all designated persons and relatives.
- Closure is in anticipation of the un-audited financial results for the quarter ended June 30, 2026.
- The window will reopen 48 hours after the public declaration of the financial results.
- Board meeting date for result consideration to be announced separately.
Financial Performance
Revenue Growth by Segment
The NCE (New Chemical Entity) segment is currently in the research phase with negligible revenue; the US subsidiary Suven Neurosciences, Inc. reported total revenues of only INR 17.10 Lakhs for FY25. Historically, the consolidated entity (pre-demerger) had an operating income of INR 663.63 Cr in FY19, but the revenue-generating CRAMS business was moved to Suven Pharmaceuticals Ltd, leaving SUVEN with research-heavy, low-revenue operations.
Geographic Revenue Split
Revenue is primarily derived from international markets through its US-based subsidiary, Suven Neurosciences, Inc., which contributed INR 17.10 Lakhs in FY25. The company maintains assets in all major global markets to support its clinical trial pipeline.
Profitability Margins
Profitability is deeply negative due to high R&D intensity. Consolidated net loss after tax for the US subsidiary was INR 11,366.52 Lakhs in FY25. Standalone H1 FY26 loss before tax widened by 61.3% to INR 3,022.38 Lakhs from INR 1,873.78 Lakhs YoY, as the company has no significant commercial products to offset research costs.
EBITDA Margin
Core operating profitability is negative; consolidated operating loss before working capital changes worsened by 28.2% to INR 16,477.49 Lakhs in FY25 compared to INR 12,853.51 Lakhs in FY24. This reflects the high cash burn rate inherent in clinical-stage biopharmaceutical development.
Capital Expenditure
Standalone payments for the purchase of property, plant, and equipment (PPE) amounted to INR 213.74 Lakhs in H1 FY26, compared to INR 17.64 Lakhs in H1 FY25, representing a significant increase in infrastructure investment to support ongoing research activities.
Credit Rating & Borrowing
CRISIL has placed the company on 'Watch with developing implications' following the demerger. Historically, the company maintained a healthy financial profile with an interest coverage ratio of 44.13x in FY19, but current operations rely heavily on equity funding rather than debt, as evidenced by the INR 299.54 Cr raised through equity in H1 FY26.
Operational Drivers
Raw Materials
Specific chemical reagents and active pharmaceutical ingredients (APIs) required for NCE development; while specific names are not listed, 'Cost of materials consumed' is a standard line item for their lab-scale manufacturing and clinical batch production.
Capacity Expansion
The company focuses on R&D capacity rather than industrial volume. Current focus is on advancing SUVN-502 through clinical trials. The company raised INR 299.54 Cr in H1 FY26 specifically to provide liquidity for these ongoing clinical obligations and research operations.
Raw Material Costs
Raw material costs are minimal compared to R&D and employee expenses; standalone cost of materials consumed is part of the broader R&D expenditure which drives the INR 160.75 Cr annual consolidated loss.
Manufacturing Efficiency
Not applicable as the company is in the clinical research stage; efficiency is measured by trial progression and patent filings rather than manufacturing throughput.
Logistics & Distribution
Not applicable for the current pre-commercial stage of their lead NCE products.
Strategic Growth
Growth Strategy
Growth is predicated on the successful commercialization or out-licensing of NCEs like SUVN-502. The strategy involves securing external funding (INR 299.54 Cr raised recently) to complete Phase 2/3 trials and leveraging a 25% stake in Rising Pharma Holdings Inc. to create a pathway for generic drug assets.
Products & Services
New Chemical Entities (NCEs) for neurodegenerative disorders, specifically SUVN-502 for Alzheimer's disease and other forms of dementia.
Brand Portfolio
SUVEN, Suven Neurosciences.
New Products/Services
Lead candidate SUVN-502 is the primary focus for future revenue contribution; success in Alzheimer's trials would transition the company from pre-revenue to a high-growth biopharma player.
Market Expansion
Targeting major global markets for CNS (Central Nervous System) disorders, with a physical presence and subsidiary in the USA to manage clinical trials and regulatory filings.
Market Share & Ranking
Not disclosed for the NCE segment due to its developmental stage.
Strategic Alliances
Maintains a 25% stake in Rising Pharma Holdings Inc. (a joint venture with Shore Pharma Investments, LLC) to acquire and develop generic drug assets.
External Factors
Industry Trends
The biopharmaceutical industry is shifting toward specialized CNS treatments. While the sector is growing, it is characterized by high failure rates in clinical trials. Suven is positioned as a pure-play R&D house following its demerger from the revenue-stable CRAMS business.
Competitive Landscape
Competes with global big pharma and biotech firms developing Alzheimer's treatments; Suven's advantage lies in its specialized focus on neurodegenerative disorders.
Competitive Moat
The moat is based on intellectual property and patents for NCEs in major markets. This is sustainable only as long as patents are active and clinical data remains superior to emerging competitors.
Macro Economic Sensitivity
Highly sensitive to global economic conditions and the availability of venture/equity funding for biopharma, as the company requires continuous external capital to survive 5+ years of losses.
Consumer Behavior
Increasing global aging population is driving demand for dementia and Alzheimer's treatments, creating a massive potential patient base for successful NCEs.
Geopolitical Risks
Exposure to US regulatory changes (FDA) and trade policies, as the primary research and future market for their NCEs is the United States.
Regulatory & Governance
Industry Regulations
Strict adherence to Ind AS financial reporting and clinical trial regulations set by the FDA (USA) and DCGI (India). The company is subject to the Companies Act, 2013, regarding internal financial controls.
Taxation Policy Impact
The company carries forward significant losses, resulting in deferred tax assets; however, recognition is subject to the probability of future taxable profits.
Legal Contingencies
The company identifies 'Contingencies' as a key area of management judgment, though specific pending court case values were not detailed in the provided snippets.
Risk Analysis
Key Uncertainties
The 'Going Concern' assumption is the primary uncertainty; the company has incurred continuous losses for 5 years and is entirely dependent on the success of future fundraising and clinical trials.
Geographic Concentration Risk
High concentration in the USA for research operations and future revenue, with the US subsidiary holding assets of INR 1,776.28 Lakhs.
Third Party Dependencies
High dependency on collaborative partners for clinical trials and future commercialization; failure to retain key personnel or partners would halt operations.
Technology Obsolescence Risk
Risk that new medical breakthroughs or alternative therapies (e.g., gene therapy) could make SUVN-502 obsolete before it reaches the market.
Credit & Counterparty Risk
Trade receivables are low (INR 26.87 Lakhs decrease in H1 FY26), indicating limited credit risk but also reflecting the lack of commercial sales.
